Phase II trial

June 4, 2020

Medium sized ~100 patients: Aims to find out: does the treatment work well enough to test in larger phase 3 trial, which types of cancer does the treatment work for, Side effects and how to manage them, more information on best dose.

Connect

Connect with us

The Mark Foundation Institute for Integrated Cancer Medicine (MFICM) at the University of Cambridge aims to revolutionise cancer care by affecting patients along their treatment pathway.

Find out more

Connect